Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20220252574IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USING
US 11.08.2022
Int.Class G01N 33/50
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Appl.No 17629309 Applicant University of Louisville Research Foundation, Inc. Inventor Kevin Joseph Sokoloski

Immunomodulatory compositions that include at least one alphavirus capsid protein and methods of using such immunomodulatory compositions. In one aspect, methods of immunomodulating IL-1/TLR signaling in a cell are provided. Such methods typically include contacting the cell with an alphavirus capsid protein or a portion thereof, thereby immunomodulating IL-1/TLR signaling in the cell.

2.20220251085CYSTEINE BINDING COMPOSITIONS AND METHODS OF USE THEREOF
US 11.08.2022
Int.Class C07D 473/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
473Heterocyclic compounds containing purine ring systems
Appl.No 17629303 Applicant University of Virginia Patent Foundation Inventor Ku-Lung Hsu

Purine-derived covalent probes (e.g., halo or di-halo-substituted purine based covalent probes) and related ligands are described. The compounds can be used to identify reactive nucleophilic amino acid residues, such as reactive cysteine residues, in proteins and to modify the activity of proteins with reactive nucleophilic amino acid residues (e.g., reactive cysteine residues) via the formation of protein adducts comprising the ligands Modified proteins prepared from the probes and ligands are also described.

3.20220249473A NOVEL THERAPY FOR ERYTHROPOIETIC PROTOPORPHYRIA (EPP) AND X-LINKED PROTOPORPHYRIA (XLP)
US 11.08.2022
Int.Class A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Appl.No 17612638 Applicant Xiaochao MA Inventor Xiaochao MA

Disclosed are novel compositions and methods of using the same for the treatment of Erythropoiefic protoporphyria (EPP) and X-linked protoporphyria (XLP). Disclosed are methods and compositions related to treating Erythropoietic protoporphyria and X-linked protoporphyria. Also described are therapeutic agents that can inhibit ABCG2. For example, provided herein are therapeutic agents defined by Formula I.

4.20220249557Vaccine and Uses thereof in Cell Therapy
US 11.08.2022
Int.Class A61K 35/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Appl.No 17592601 Applicant Innovative Cellular Therapeutics Holdings, Ltd. Inventor Yang Li

The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.

5.WO/2022/165608ANTI-SYNUCLEINOPATHY PEPTIDE AND METHODS TO TREAT NEURODEGENRATIVE DISEASES
WO 11.08.2022
Int.Class A61K 47/66
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
66the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
Appl.No PCT/CA2022/050175 Applicant UNIVERSITY OF BRITISH COLUMBIA Inventor WANG, Yu Tian
Disclosed is a method of treating a neurodegenerative disease such as Parkinson's disease, diffuse Lewy body disease, transitional Lewy body dementia, and multiple system atrophy in a subject. The method comprises administering to the subject a therapeutically effective amount of a peptide comprising an α-synuclein binding domain operably linked to a protein transduction domain and a proteasomal targeting domain, wherein the α-synuclein binding domain is derived from a reversed sequence of β-synuclein. Other methods, as well as uses and compositions, are disclosed.
6.WO/2022/165578ADDITIVE FOR PRESERVING CELLS, TISSUE AND/OR FOODSTUFFS, AND USE
WO 11.08.2022
Int.Class A01N 3/02
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
3Preservation of plants or parts thereof, e.g. inhibiting evaporation, improvement of the appearance of leaves; Grafting wax
02Keeping cut flowers fresh chemically
Appl.No PCT/BR2022/050037 Applicant PROTEIMAX BIO TECHNOLOGY ISRAEL LTD Inventor HEIMANN, Andrea Sterman
The present invention pertains to the fields of biotechnology, phytochemistry and food technology, and provides an additive for preserving cells, tissue and/or foodstuffs and the use of a synthetic peptide for preparing said additive. Among other applications, the invention is useful for increasing the shelf life of foodstuffs and providing greater food safety. In one embodiment, the additive of the invention provides substantial preservation of fruit through a single application of the additive, providing the treatment of plants or foodstuffs in order to prevent the occurrence of blight such as bacteria or fungi such as, for example, those related to the rotting of fruit, including strawberries, and Xylella fastidiosa in coffee plants and orange groves. In one embodiment, the additive of the invention provides substantial preservation of flowers or inflorescences through a single application of the additive, providing an alternative against the rapid wilting, rotting or appearance of fungi associated with the storage, transport and/or medicinal processing of flowers or inflorescences of phytochemical interest, including gerbera and cannabis, inter alia. In one embodiment, the present additive provides substantial preservation of the metabolic state of shoots or seedlings, in addition to delaying the seed germination process when said additive is applied, and is therefore useful for synchronizing germination and adjusting the moment of planting or germination, among other agricultural or botanical advantages.
7.WO/2022/167003METHOD FOR USING TANGENTIAL FLOW ULTRAFILTRATION TECHNOLOGY TO PREPARE CONTROLLABLE HIGH CONCENTRATION SILK FIBROIN SOLUTION
WO 11.08.2022
Int.Class C07K 14/435
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
Appl.No PCT/CN2022/082618 Applicant FAVORSUN MEDICAL TECH. (SUZHOU) CO., LTD. Inventor YANG, Wenhua
Provided is a method for using tangential flow ultrafiltration technology to prepare a controllable high concentration high molecular weight silk fibroin solution. The steps comprise: obtaining a silk fibroin inorganic salt solution; performing membrane clarification treatment on the silk fibroin inorganic salt solution; performing desalting treatment on the silk fibroin inorganic salt solution, wherein a clear liquid obtained after the membrane clarification treatment is filtered by means of a tangential flow filtration system; concentrating the silk fibroin solution, to obtain a high concentration high molecular weight silk fibroin aqueous solution. Compared to the prior art, the present invention implements desalting and concentrating on a silk fibroin salt solution by means of tangential flow technology, and thereby directly obtains a silk fibroin aqueous solution having a number average molecular weight of 80kDa – 200kDa. The properties of the obtained material are improved in all aspects. In addition, the method of the present invention significantly increases efficiency, reduces costs, and facilitates the development of silk fibroin materials.
8.WO/2022/167798MOLECULE
WO 11.08.2022
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
Appl.No PCT/GB2022/050280 Applicant AUTOLUS LIMITED Inventor MCKENZIE, Callum
The present invention provides a molecule which comprises a Fas-binding domain linked to an intracellular retention signal. When expressed in a cell, the molecule inhibits Fas expression at the cell surface and therefore Fas:FasL-mediated apoptosis.
9.WO/2022/170033ENGINEERED NATURAL LIGAND-BASED CAR: DIRECTED EVOLUTION OF THE STRESS-RECEPTOR NKP30
WO 11.08.2022
Int.Class A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
Appl.No PCT/US2022/015214 Applicant THE TRUSTEES OF DARTMOUTH COLLEGE Inventor BUTLER, Savannah, E.
Directed evolution using yeast display was employed to isolate novel NKp3O variants that bind to B7H6 with higher affinity compared to the native receptor but retain its fast association and dissociation profile. Two variants, CC3 and CCS, were expressed as soluble Fc-fusion proteins and CARs containing CD28 and CD3ζ intracellular domains. These Fc fusion protein forms of NKp30 and its variants were better able to bind tumor cells expressing low levels of B7H6 than TZ47, and exhibited improved in vitro tumor cell killing relative to NKp30. Also, CAR T cells expressing the engineered variants produced unique cytokine signatures in response to multiple tumor types expressing B7H6 compared to both NKp30 and TZ47. These findings suggest that natural CAR receptors can be fine-tuned to produce more desirable signaling outputs while maintaining evolutionary advantages in ligand recognition relative to scFvs.
10.WO/2022/170063IL-15 FUSION PROTEINS AND METHODS OF MAKING AND USING SAME
WO 11.08.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/US2022/015271 Applicant SALUBRIS BIOTHERAPEUTICS, INC. Inventor LI, John
The disclosure provides recombinant fusion proteins comprising an antigen binding domain specific for CTLA-4, an IL-15Ra sushi domain and IL-15. The disclosure further provides methods of using these recombinant fusion proteins in the treatment of cancer.